CIK 0001540159 · Non-accelerated filer<br>Smaller reporting company
Edesa Biotech, Inc.
Sign in to watch- Ticker
- EDSA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Sep 30
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- (905) 475-1234
- Business address
- C/O FASKEN MARTINEAU DUMOULIN LLP, 333 BAY STREET, SUITE 2400, TORONTO, Ontario, Canada, M5H 2T6
- Former names
- Stellar Biotechnologies, Inc.
- 4 Grant or award Chief Executive Officer acquired 4,630 shares (grant or award)
- SC 13D/A Stake Beneficial Ownership Report
- 4 Derivatives Options or other derivatives
- 8-K Event Material agreement · Agreement ended · New debt or obligation · Unregistered share sale · Shareholder rights changed · Bylaws or fiscal year change
- 424B5 Offering Prospectus
- 8-K Event Material agreement · Agreement ended
- 4 Grant or award Chief Executive Officer acquired 3,300 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 3,055 shares (grant or award)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Grant or award Chief Executive Officer acquired 3,317 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 4,015 shares (grant or award)
- 8-K Event Regulation FD disclosure · Other events
- 4 Grant or award Chief Executive Officer acquired 4,785 shares (grant or award)
- SC 13G Stake Amended Statement of Ownership
- S-8 Other Securities Offered to Employees in Benefit Plans
- 8-K Event Executive or director change
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Grant or award Chief Executive Officer acquired 3,083 shares (grant or award)
Page 8 of 38 · 753 filings